# OnCo record atlantis (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/atlantis/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "atlantis", "NCT02566993" ;
  schema:name "ATLANTIS"@en ;
  schema:description "Lurbinectedin's confirmatory trial missed its survival goal, but the drug stayed on the market because the combination tested was not the approved monotherapy dose."@en ;
  schema:url <https://onco.cc/trials/atlantis/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02566993> ;
  onco:status "negative" ;
  onco:tag "lesson:combination-dose" ;
  onco:phase "3" ;
  schema:startDate "2016-08-30" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/topotecan/> ;
  onco:companies <https://onco.cc/companies/pharmamar/>, <https://onco.cc/companies/jazz/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-atlantis-lancet-respir-med-2023/> .